CB 839

Drug Profile

CB 839

Alternative Names: CB839

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Calithera Biosciences
  • Developer Calithera Biosciences; National Cancer Institute (USA)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Renal cell carcinoma
  • Phase I/II Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
  • Phase I Haematological malignancies; Leukaemia; Solid tumours

Most Recent Events

  • 05 Feb 2018 Calithera plans the phase II CANTATA trial for Renal cell carcinoma (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Q2 2018 (PO) (NCT03428217)
  • 05 Feb 2018 Efficacy data from a phase II trial in Renal cell carcinoma released by Calithera Biosciences
  • 05 Feb 2018 Updated efficacy and safety data from a phase I trial in Solid tumours released by Calithera Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top